1. Home
  2. SURG vs CTSO Comparison

SURG vs CTSO Comparison

Compare SURG & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SurgePays Inc.

SURG

SurgePays Inc.

HOLD

Current Price

$0.82

Market Cap

20.3M

ML Signal

HOLD

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.67

Market Cap

45.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SURG
CTSO
Founded
2006
1997
Country
United States
United States
Employees
20
N/A
Industry
Advertising
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.3M
45.7M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
SURG
CTSO
Price
$0.82
$0.67
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$9.75
$5.38
AVG Volume (30 Days)
139.2K
62.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$22,503,908.00
Revenue This Year
$3.78
$7.29
Revenue Next Year
$113.46
$8.91
P/E Ratio
N/A
N/A
Revenue Growth
N/A
48.53
52 Week Low
$0.75
$0.60
52 Week High
$3.47
$1.39

Technical Indicators

Market Signals
Indicator
SURG
CTSO
Relative Strength Index (RSI) 41.12 41.61
Support Level $0.77 $0.62
Resistance Level $0.95 $0.74
Average True Range (ATR) 0.07 0.05
MACD 0.03 -0.01
Stochastic Oscillator 47.15 22.84

Price Performance

Historical Comparison
SURG
CTSO

About SURG SurgePays Inc.

Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: